News

Article

BASF Announces Plans to Expand PVP Facilities

BASF announced that it would invest $65 million to improve its PVP manufacturing facilities, as well as add production to its Shanghai facility.

 

BASF announced on Jan. 22, 2015 that it planned to invest up to €56 million ($65 million USD) in the expansion of its Polyvinyl pyrrolidone (PVP) value chain over the course of the next four years. PVP is a polymer used in the pharmaceutical industry because of its binding properties. The expansion will allow BASF to increase production by 6000 metric tons with improvements to facilities in Ludwigshafen, Germany and Geismar, Louisiana, USA, as well as adding the technology to produce PVP at its Shanghai, China facility.

PVP is a water-soluble polymer that can absorb large quantities of water;, it is temperature-resistant, pH-stable, non-ionic, and colorless. The binding abilities of BASF’s line of PVP products, called Kollidon, enable individual active ingredients of a tablet to form a homogenous entity and as a disintegrant it ensires ensures that the tablets break up in liquid and release the active ingredient quickly.

“With this investment, we are actively participating in the strongly growing PVP market, especially within the pharmaceutical industry,” said Saori Dubourg, president of BASF’s nutrition and health division, in a press release.

Source: BASF

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content